[Neuroendocrine differentiation in adenocarcinoma of prostate during combined androgen blockade therapy: a case report]

Hinyokika Kiyo. 2005 Jan;51(1):33-5.
[Article in Japanese]

Abstract

Prostatic neuroendocrine (NE) carcinoma is a rare disease with a poor prognosis because of its rapid progression and the androgen-independent characteristic, for which no successful therapy is available presently. We report a case of NE differentiated prostate cancer, which was diagnosed as adenocarcinoma initially and progressed with NE differentiation during the combined androgen blockade therapy.

Publication types

  • Case Reports
  • English Abstract

MeSH terms

  • Adenocarcinoma / drug therapy
  • Adenocarcinoma / pathology*
  • Aged
  • Aged, 80 and over
  • Androgen Antagonists / therapeutic use*
  • Carcinoma, Neuroendocrine / pathology*
  • Cell Transformation, Neoplastic / pathology*
  • Drug Resistance, Neoplasm
  • Humans
  • Magnetic Resonance Imaging
  • Male
  • Neoplasm Staging
  • Prostatic Neoplasms / drug therapy
  • Prostatic Neoplasms / pathology*

Substances

  • Androgen Antagonists